What is PreciThera?
PreciThera, Inc. is a biotechnology company dedicated to the development of therapies for rare bone diseases. The company leverages a synergistic approach, integrating advanced computational technology with a profound understanding of disease pathology. Its primary focus is on heterogeneous genetic disorders that significantly impact bone function, aiming to provide meaningful therapeutic interventions for both skeletal and extraskeletal manifestations experienced by patients. The company's commitment to understanding novel biology positions it to develop targeted strategies that can substantially improve patient outcomes.
How much funding has PreciThera raised?
PreciThera has raised a total of $29M across 1 funding round:
Series A
$29M
Series A (2017): $29M with participation from Emerillon Capital, Sanderling Ventures, Fonds de solidarité FTQ, Arix Bioscience, and CTI Life Sciences
Key Investors in PreciThera
Emerillon Capital
Emerillon Capital is a venture capital firm that likely focuses on early-stage investments within the biotechnology and life sciences sectors, given its association with PreciThera's funding round.
Sanderling Ventures
Sanderling Ventures is a pioneering investment firm founded in 1979, specializing in building new biomedical companies and focusing on early-stage financing and active management in the biomedical sector.
CTI Life Sciences
CTI Life Sciences Fund is a prominent Canadian biotech venture capital firm that focuses on catalyzing innovative ideas and assets into scalable biotech companies, with investments across various therapeutic modalities.
What's next for PreciThera?
With the recent infusion of major strategic capital, PreciThera is poised to accelerate its research and development initiatives. The enterprise-level funding suggests a focus on scaling operations, advancing clinical trials, and potentially expanding its pipeline of therapies for rare bone diseases. This strategic investment is likely to bolster the company's efforts in translating its unique biological insights and computational tools into tangible treatments, aiming to make a significant impact on patients with debilitating conditions. The company's trajectory indicates a strong emphasis on innovation and market penetration within the specialized field of rare genetic bone disorders.
See full PreciThera company page
